Previous work on the co-expression of CLDN18.2 and other biomarkers in advanced esophagogastric adenocarcinoma has been biased by the use of different antibodies and positivity thresholds [49,51]. The gene discussed is CLDN18; the disease is gastroesophageal junction adenocarcinoma.